Perspective Confidentiality Disclosure Reliability Courtesy
… is likely to stimulate some ferment among the prostate cancer advocacy community. (See the article
entitled “Does prostate screening make sense for you?“)
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: intervention, mortality, risk, screening | 3 Comments »
… there are several new articles on research into clinical aspects of prostate cancer available on line from the UroToday International Journal.
This issue of UTIJ contains publications from the annual meeting of the Urological Research Society, which concluded on September 20th. None of the articles appear to be of any great significance on their own, but taken as [...]
Filed under: Diagnosis, Management, Treatment | 1 Comment »
More news of a relatively theoretical nature today:
The relevance of nuclear roundness variance in predicting risk of disease progression
Incorporation of the PCA3 gene marker into the PCPT risk calculator
Saving the neurovascular bundles has no impact on long-term continence
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: PCA3, progression, nuclear roundness, Her-2/neu, continence, neurovascular bundles | 1 Comment »
It appears that urinary continence after radical prostatectomy (RP) may be associated with preoperative and postoperative membranous urethral length (MUL), percent change in MUL, and postoperative urethral, and periurethral fibrosis.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: incontinence urethra length | No Comments »
The news update for this weekend is largely of a “theoretical” as opposed to a “practical” nature. We have therefore kept the discussion brief and referred readers to the source material for more information.
Filed under: Diagnosis, Management, Tips, Treatment | Tagged: DNA index, Her2/neu, incidence, Korea, PSA, urology education | No Comments »
A couple of days ago we mentioned an abstract of a paper we had seen by Suardi et al. that discussed the “misclassification” of patients as being appropriate for active surveillence (AS). We have now had the chance to read this entire paper and are clearer about this analysis.
Filed under: Diagnosis, Management, Treatment | Tagged: active surveillance, criteria | 1 Comment »
Many prostate cancer patients use vitamin D supplements as a way to assist prevention of bone matrix deterioration, to prevent the potential for bone fractures, and simply to ensure avoidance of vitamin D deficiency.
Tangpricha has recently updated his chapter on vitamin D deficiency and related disorders on eMedicine, and this review may be of interest to [...]
Filed under: Living with Prostate Cancer, Management | Tagged: vitamin D deficiency | No Comments »
According to HealthDay, a letter to the editor published today in the New England Journal of Medicine reports the very rare occurrence of inflammatory eye disease in patients being treated with bisphosphonates, e.g., alendronate (Fosamax), pamidronate (Aredia), zoledronic acid (Zometa), and others.
Filed under: Uncategorized | Tagged: bisphosphonate, inflammatory eye disease | No Comments »
Additional, non-ASTRO-related news today includes the following:
Screening, treatment, and mortality in Medicare-eligible populations
Genetic variants and relationships to clinical and pathological variables
The application of MRI in prostate cancer management
Predictors of aggressive biochemical recurrence after radical prostatectomy
Filed under: Management, Treatment | Tagged: aggressive, genetic variants, magnetic resonance, mortality, MRI, prediction, recurrence | No Comments »
Prostate cancer reports from the 50th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), held in Boston, have kindly been provided by Eyad Abu-Isa, MD, a resident in radiation oncology at the University of Michigan
This year’s scientific sessions concluded on Wednesday with two sessions focused on prostate cancer therapies and long-term outcomes and one afternoon session focused [...]
Filed under: Management, Treatment | Tagged: androgen deprivation, ASTRO, brachytherapy, external beam radiation | 1 Comment »
